Enhanced Anticancer Effect of Temozolomide through Synergistic Combination with Diltiazem in Neuroblastoma (SH-SY5Y) Cell Line

Basit Öğe Kaydı
dc.contributor.authorKarademir, Mustafa
dc.contributor.authorSurardamar, Saime
dc.date.accessioned2025-05-04T16:26:32Z
dc.date.available2025-05-04T16:26:32Z
dc.date.issued2023
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractObjective: This study aimed to assess the enhanced anticancer effect of Temozolomide (TMZ) through a synergistic combination with Diltiazem (DTZ) in the neuroblastoma cell line (SH-SY5Y). Material and Methods: The SH-SY5Y neuroblastoma cell line was cultured in a DMEM medium. TMZ and DTZ stock solutions were prepared and diluted to obtain different concentrations. The XTT assay was performed to evaluate cell viability. Cells were treated with TMZ alone or with DTZ for 24 and 48 hours. Viability was measured using the XTT-formazan product, and statistical analysis was performed. Results: The viability of neuroblastoma cells treated with TMZ alone and TMZ+DTZ combination was assessed. At 24 hours, TMZ showed no cytotoxic effect, while DTZ showed a low cytotoxic impact. At 48 hours, TMZ and TMZ+DTZ combination exhibited significant cytotoxic effects. The cytotoxic effects were concentration-dependent and time-dependent. DTZ alone showed significant cytotoxic effects on neuroblastoma cells at specific concentrations. Conclusion: The study demonstrated that TMZ alone and combined with DTZ had a significant cytotoxic effect on neuroblastoma cells. The combination of TMZ and DTZ may enhance the anticancer effect of TMZ and overcome drug resistance in neuroblastoma treatment. DTZ, a P-glycoprotein inhibitor, could prevent the efflux of TMZ from cancer cells, increasing its concentration and effectiveness.
dc.description.abstract[No abstract available]
dc.identifier.doi10.7197/cmj.1313269
dc.identifier.doihttps://doi.org/10.7197/cmj.1313269
dc.identifier.endpage51
dc.identifier.issn1305-0028
dc.identifier.issue2
dc.identifier.startpage46
dc.identifier.urihttps://hdl.handle.net/20.500.12418/32786
dc.identifier.volume45
dc.language.isoen
dc.publisherSivas Cumhuriyet Üniversitesi
dc.relation.ispartofCumhuriyet Tıp Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_DergiPark_20250504
dc.subjectTemozolamide
dc.subjectDiltiazem
dc.subjectNeuroblastoma
dc.subjectP-Gp
dc.subjectDrug resistance
dc.subjectCytotoxity
dc.titleEnhanced Anticancer Effect of Temozolomide through Synergistic Combination with Diltiazem in Neuroblastoma (SH-SY5Y) Cell Line
dc.typeResearch Article

Dosyalar

Koleksiyon

DergiPark